Ainos, Inc. (AIMD) - Q1 2026 10-Q Summary
Business Context and Reporting Period
This filing covers the quarterly period ended March 31, 2026. Ainos, Inc. is a dual-platform company developing AI-enabled olfactory sensing technologies ("AI Nose" or "SmellTech") and immune therapeutics ("VELDONA"). The company operates as a single segment and is classified as a smaller reporting company. As of May 13, 2026, there were 8,524,542 shares of common stock issued and outstanding.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Revenue | $161 | $106,207 |
| Net Loss | $(2,459,800) | $(3,286,022) |
| Net Loss Per Share (Basic/Diluted) | $(0.41) | $(1.04) |
| Cash and Cash Equivalents (End of Period) | $2,841,422 | $2,628,286 |
| Total Assets | $22,081,583 | $20,871,108 |
| Total Liabilities | $16,389,637 | $13,308,526 |
| Stockholders' Equity | $5,691,946 | $7,562,582 |
| Operating Cash Flow | $(983,421) | $(1,224,578) |
Debt and Liquidity: The company holds $11,000,000 in convertible notes payable (related parties) and a new $2,812,940 loan payable to a related party. Cash increased significantly from $417,353 at year-end 2025 to $2,841,422 at March 31, 2026, primarily due to financing activities.
Material Changes vs. Prior Period
- Revenue Collapse: Revenue plummeted 99.8% to $161 from $106,207 in Q1 2025. Management attributes this to a strategic shift away from healthcare-adjacent applications toward industrial deployments (semiconductors, robotics), which are in earlier commercialization stages.
- Reduced Net Loss: Net loss decreased by 25% to $2.46 million, driven by a 61% reduction in Selling, General, and Administrative (SG&A) expenses ($593k vs $1.53M), largely due to lower share-based compensation and reduced insurance/reporting fees.
- Financing Activity: The company raised $3.41 million in financing activities, including $2.81 million from a new related-party loan and $601,600 from an At-The-Market (ATM) offering. This contrasts with only $14,605 in financing proceeds in Q1 2025.
- Debt Restructuring: A $2,000,000 convertible note previously classified as non-current was reclassified as current. A new $2.81 million loan was secured from ASE Test, Inc.
Outlook, Risks, and Management Commentary
Management Priorities: The focus for 2026 is advancing AI Nose commercialization in industrial settings (semiconductor manufacturing, robotics) and managing VELDONA programs in a capital-efficient manner. Recent developments include a $2.1 million commercial arrangement for backend semiconductor manufacturing and pilot programs in front-end environments.
Liquidity and Going Concern: While cash reserves improved to $2.84 million, the filing explicitly states that substantial doubt exists about the company's ability to continue as a going concern for at least one year. The company expects to incur additional losses and negative operating cash flows. Future operations depend on generating sufficient cash flow or securing additional equity/debt financing, which is not assured.
Risks:
- Foreign Currency: Operations in Taiwan expose the company to exchange rate fluctuations.
- Trade Policy: Potential tariffs and trade policy changes (specifically mentioning the Trump Administration) could impact component costs and demand.
- Intellectual Property: The industry is characterized by extensive patent litigation risks.
Investor Verification Checklist
- Going Concern Status: Verify the company's ability to secure further funding given the explicit "substantial doubt" disclosure and reliance on related-party financing.
- Revenue Recognition: Confirm the timeline for revenue recognition from the new $2.1 million semiconductor contract and the transition from healthcare to industrial revenue streams.
- Related Party Transactions: Review the terms of the $2.81 million loan and $11 million convertible notes held by related parties (ASE Test, Inc.) to understand repayment obligations and conversion risks.
- ATM Offering Capacity: Check remaining capacity under the At-The-Market offering agreement, as the company recently increased the aggregate offering price limit.
- Share Dilution: Monitor the impact of the recent 1-for-5 reverse stock split (effective June 2025) and potential future dilution from warrant exercises and convertible note conversions.